bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) was the target of a large decrease in short interest in August. As of August 15th, there was short interest totalling 291,900 shares, a decrease of 58.8% from the July 31st total of 708,000 shares. Based on an average trading volume of 108,200 shares, the days-to-cover ratio is currently 2.7 days. Currently, 4.5% of the company’s shares are short sold.
bioAffinity Technologies Stock Down 1.9 %
Shares of BIAF traded down $0.03 during mid-day trading on Thursday, hitting $1.55. 34,688 shares of the company’s stock were exchanged, compared to its average volume of 142,856. The firm has a fifty day moving average of $2.10 and a two-hundred day moving average of $2.15. bioAffinity Technologies has a twelve month low of $0.95 and a twelve month high of $3.62. The stock has a market cap of $18.07 million, a price-to-earnings ratio of -1.67 and a beta of 2.95. The company has a quick ratio of 2.21, a current ratio of 2.22 and a debt-to-equity ratio of 0.14.
Wall Street Analyst Weigh In
Separately, Maxim Group initiated coverage on shares of bioAffinity Technologies in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $6.00 price objective on the stock.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC purchased a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies at the end of the most recent reporting period. 1.64% of the stock is owned by institutional investors.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- What is the Dogs of the Dow Strategy? Overview and Examples
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Investing In Automotive Stocks
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Investing in Construction Stocks
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.